Chronic kidney disease (CKD) is associated with an increase in inflammatory cytokines and can result in cachexia with loss of muscle and fat stores. We previously demonstrated the efficacy of treating a model of cancer cachexia with ghrelin and a ghrelin receptor agonist. Currently, we examine a surgical model of CKD in rats, resulting in uremia and decreased accrual of lean body mass. Treatment with ghrelin and two ghrelin receptor agonists (BIM-28125 and BIM-28131) resulted in increased food intake and an improvement in lean body mass accrual that was related in part to a decrease in muscle protein degradation as assessed by muscle levels of the 14-kDa actin fragment resulting from cleaved actomyosin. Additionally, there was a decrease in circulating inflammatory cytokines in nephrectomized animals treated with ghrelin relative to saline treatment. Ghrelin-treated animals also had a decrease in the expression of IL-1 receptor in the brainstem and a decrease in expression of prohormone convertase-2, an enzyme involved in the processing of proopiomelanocortin to the anorexigenic peptide ␣-MSH. We conclude that ghrelin treatment in uremia results in improved lean mass accrual in part due to suppressed muscle proteolysis and possibly related to antiinflammatory effects. (Endocrinology 149: 827-835, 2008) P ATIENTS WITH CHRONIC kidney disease (CKD) often exhibit symptoms of anorexia, loss of lean body mass, and increased energy expenditure, matching the syndrome of cachexia seen in other chronic diseases such as cancer, chronic heart failure, and AIDS (1, 2). In addition, patients with CKD-induced uremia frequently exhibit a dangerous decrease in protein nutritional status, including decreased levels of albumin and prealbumin as well as catabolism of actinomycin in muscle tissue via caspase-3 and the ubiquitinproteasome pathway (3-8). As with other diseases associated with cachexia, these catabolic processes seen in CKD are linked to systemic inflammatory changes, including increases in acute-phase reactants such as C-reactive protein and inflammatory cytokines (9 -15). Indeed, this inflammation is felt to be in the causative pathway of the production of cachexia (16 -19).
Chronic kidney disease (CKD) is associated with an increase in inflammatory cytokines and can result in cachexia with loss of muscle and fat stores. We previously demonstrated the efficacy of treating a model of cancer cachexia with ghrelin and a ghrelin receptor agonist. Currently, we examine a surgical model of CKD in rats, resulting in uremia and decreased accrual of lean body mass. Treatment with ghrelin and two ghrelin receptor agonists (BIM-28125 and BIM-28131) resulted in increased food intake and an improvement in lean body mass accrual that was related in part to a decrease in muscle protein degradation as assessed by muscle levels of the 14-kDa actin fragment resulting from cleaved actomyosin. Additionally, there was a decrease in circulating inflammatory cytokines in nephrectomized animals treated with ghrelin relative to saline treatment. Ghrelin-treated animals also had a decrease in the expression of IL-1 receptor in the brainstem and a decrease in expression of prohormone convertase-2, an enzyme involved in the processing of proopiomelanocortin to the anorexigenic peptide ␣-MSH. We conclude that ghrelin treatment in uremia results in improved lean mass accrual in part due to suppressed muscle proteolysis and possibly related to antiinflammatory effects. (Endocrinology 149: 827-835, 2008) P ATIENTS WITH CHRONIC kidney disease (CKD) often exhibit symptoms of anorexia, loss of lean body mass, and increased energy expenditure, matching the syndrome of cachexia seen in other chronic diseases such as cancer, chronic heart failure, and AIDS (1, 2) . In addition, patients with CKD-induced uremia frequently exhibit a dangerous decrease in protein nutritional status, including decreased levels of albumin and prealbumin as well as catabolism of actinomycin in muscle tissue via caspase-3 and the ubiquitinproteasome pathway (3) (4) (5) (6) (7) (8) . As with other diseases associated with cachexia, these catabolic processes seen in CKD are linked to systemic inflammatory changes, including increases in acute-phase reactants such as C-reactive protein and inflammatory cytokines (9 -15) . Indeed, this inflammation is felt to be in the causative pathway of the production of cachexia (16 -19) .
CKD is similar to other diseases associated with cachexia in that the symptoms of cachexia in CKD are associated with a decrease in quality of life and an increase in mortality (20 -26) . Unfortunately, no single agent has emerged as a beneficial treatment for cachexia (27) . One potential treatment for cachexia in multiple disease states is the use of the orexigenic hormone ghrelin (28, 29). Although ghrelin levels are already elevated above normal in cachexia-associated disease states such as cancer, heart failure, and CKD, administration of supraphysiological doses of ghrelin has been shown to increase food intake in human subjects with cancer and heart failure (30 -34).
We have previously delivered ghrelin and ghrelin agonists in a rat model of cancer cachexia, demonstrating improved lean body mass retention and increases in gene expression of agouti-related peptide (AgRP) and neuropeptide Y(NPY), two orexigenic neuropeptides produced in the arcuate nucleus of the hypothalamus, an important appetite-regulating center (35).
In addition to its effects on appetite regulation, ghrelin has been shown to have antiinflammatory properties. The GH secretagogue (GHS)-1a receptor is expressed on lymphocytes, and administration of the GHS-1a agonist GHRP-2 in the setting of a mouse model of arthritis resulted in a decrease in IL-6 levels and reduced signs of joint inflammation (36). Also, macrophages that have been pretreated with ghrelin show reduced IL-6 production in response to inflammatory stimuli. In our rat model of cancer cachexia, we showed a decrease in expression of the IL-1 receptor in the hypothalamus and the brainstem after ghrelin treatment (35).
In the present experiments, we evaluated the efficacy of ghrelin and two ghrelin-receptor agonists in a rat model of surgically induced CKD. In these experiments, we demonstrated increased food intake, lean body mass retention, decreased systemic inflammation, and a decreased muscle catabolism, further establishing a role for ghrelin in the treatment of cachexia.
Materials and Methods Compounds
BIM-28131, BIM-28125, and human ghrelin were provided by IPSEN (Milford, MA) (37-39). BIM-28131 and BIM-28125 are peptide analogs that bind to the known ghrelin receptor (GHS-1a) with sub-nanomolar affinity (K i , 0.42 Ϯ 0.063 and 0.48 Ϯ 0.16 nm, respectively). In this regard, synthetic analogs show about three times greater affinity than native ghrelin (K i , 1.12 Ϯ 0.17 nm). BIM-28131 and BIM-28125 are also more potent (EC 50 , 0.71 Ϯ 0.09 and 0.98 ϩ 0.08 nm, respectively) in activating the GHS-1a receptor than native ghrelin (EC 50 , 4.2 Ϯ 1.2 nm) as assessed in vitro by calcium mobilization. BIM-28131 and BIM-28125 have greater enzymatic stability in plasma than native ghrelin (t 1/2 rat plasma was 24 vs. 1.9 h for ghrelin) and, when injected iv, are observed to have a 10-fold greater circulating half-life as compared with native ghrelin.
Experimental animals
Studies were approved by the Institutional Animal Care and Use Committee of the Oregon Health and Science University and conducted according to the National Institutes of Health Guide for the Care and Use of Laboratory Animals. F344/NTacfBR male rats (Taconic Farms, Inc., Germantown, NY) were housed two per cage, fed rat chow (Diet 5001; Purina Mills, Inc., St. Louis, MO) and acclimated for at least 3 d before use.
Nephrectomy procedure
The five sixths nephrectomy was performed in two stages. For stage 1, the animals were anesthetized with standard rat cocktail and placed prone in a clean environment. A 1-cm posterior incision was made on the right flank through which the right kidney was located. For animals undergoing nephrectomy, the renal capsule was removed and the upper and lower one third of the kidney was transected and the resultant wound cauterized, leaving the middle one third of the kidney with the renal artery and vein intact. For animals receiving a sham operation, the renal capsule was opened up and cauterized to simulate the manipulations performed in the nephrectomy. The external surgical wounds were then closed via suture and allowed to recover in individual housing.
Nine days after the initial surgery, the animals were again anesthetized and placed prone in the surgical area. This time a left 1-cm incision was performed and the left kidney isolated. For animals undergoing nephrectomy, the renal capsule was removed and the vasculature was tied off with suture. The vascular bundle was then transected distal to the suture and the entire kidney removed. Any residual bleeding was cauterized. For animals in the sham group, the renal capsule was removed and cauterized. The external surgical wounds were closed with suture. Although still under anesthesia, the osmotic mini-pumps were placed in all animals. A 1-cm incision was made in the midline overlying the posterior thorax at the level of the forelimbs, and the underlying sc space was opened via blunt dissection. The osmotic minipumps were placed inside and the incision closed with suture. This procedure marked d 0 of treatment.
Compound administration
A continuous sterile infusion of BIM-28125, BIM-28131, human ghrelin, or saline was administered at a rate of 0.5 l/h for 14 d sc using Alzet mini-osmotic pumps (model 2002; Durect Corp., Cupertino, CA). The day before implantation of the pumps, the mean body weight of each group was determined. To calculate the concentration required for the treatment group, we considered the molecular weight of each compound, the dose (150 nmol/kg⅐d), and the pump delivery rate. Each compound was dissolved in vehicle solution (2% inactivated rat serum saline, 5% Tween 80) sonicated, and filtered through a 0.2-l syringe filter.
Body composition
Body composition was determined 2 d before the second stage of the nephrectomy or sham operation under anesthesia by dual-energy x-ray absorptiometry (DEXA, Discovery A-QDR Series; Hologic Corp., Waltham, MA) and on d 14 of compound treatment before euthanasia with CO 2 .
Tissue collection
After euthanasia, blood, brain, stomach, and muscle were collected. A subset of the rats had their hypothalami removed, preserved in RNAlater solution (Applied Biosystems, Inc. Foster City, CA), and stored at Ϫ70 C for extraction of RNA and RT-PCR analysis. A subset of the rats had their hypothalami and brainstems removed, preserved in RNAlater solution, and stored at Ϫ70 C for extraction of RNA and RT-PCR analysis. Hypothalamic blocks were dissected by making coronal transections at the optic chiasm and at the intersection between the hypothalamus and the mammillary bodies and sagittal transections along the optic tracts. Cortex was then removed at the level of the corpus callosum. Brainstem blocks were dissected by removal of the cerebellum and coronal transections at the rostral border of the pons and at the spinal cord.
Cytokine measurement
Rat serum samples were tested simultaneously for cytokines IL-1␣, IL-1␤, IL-2, IL-4, IL-6, IL-10, granulocyte-macrophage colony-stimulating factor (GM-CSF), IFN-␥, and TNF-␣ using a Bio-Plex rat cytokine 9-Plex assay (Bio-Rad Laboratories, Hercules, CA). The assay was run according to the manufacturer's instructions. In brief, the premixed standards were reconstituted in 0.5 ml of a Bio-Plex human serum standard diluent, generating a stock concentration of 50,000 pg/ml for each cytokine. The standard stock was serially diluted in the Bio-Plex rat serum standard diluent to generate eight points for the standard curve. The assay was performed in a 96-well filtration plate supplied with the assay kit. Premixed beads (50 l) coated with target capture antibodies were transferred to each well of the filtration plate and washed twice with Bio-Plex wash buffer. The samples were diluted 1:4 in the Bio-Plex serum sample diluent. Premixed standards or diluted samples (50 l) were added to each well containing washed beads. The plate was shaken and incubated at room temperature for 30 min at low speed (300 rpm). After incubation and washing, premixed biotin-conjugated detection antibodies were added to each well. Then the plate was incubated for 30 min with shaker at low speed (300 rpm). After incubation and washing, streptavidin and phycoerythrin was added to each well. The incubation was terminated after shaking for 10 min at room temperature. After washing, the beads were resuspended in 125 l Bio-Plex assay buffer. Beads were read on the Bio-Plex suspension array system (BioRad), and the data were analyzed using Bio-Plex Manager software version 3.0 with 5PL curve fitting.
RNA preparation and RT-PCR
Total RNA was extracted using QIAGEN RNeasy kits (QIAGEN, Inc., Valencia, CA), and DNA was removed from total RNA using RNase-free DNase (QIAGEN). RT reactions were prepared using a TaqMan reverse transcription kit (Applied Biosystems, Inc., Foster City, CA). For each reaction, cDNA synthesis was prepared using 500 ng RNA in a reaction containing 4 l 10ϫ RT buffer, 9 l 25 mm MgCl 2 , 8 l 10 mm dNTPs, 1.5 l 50 m random hexamers, 1 l RNase inhibitor, 1.5 l MulitScribe reverse transcriptase, and enough nuclease-free water to make 40 l. RT reactions were performed on an Eppendorf Mastercycler (Eppendorf AG, Hamburg, Germany) programmed for 25 C for 10 min, 37 C for 1 h, and 95 C for 5 min. Samples were diluted with 40 l nuclease-free water stored at 4 C until RT-PCR was performed.
RT-PCR was performed on an ABI 7300 real-time PCR system using rat-specific primer probe sets obtained from Applied Biosystems. The GenBank acquisition numbers corresponding to these primer probe sets was as follows: AgRP, XM 574228. 
GH and IGF-I assays
Serum collected at the time of euthanasia was tested for GH levels by RIA (National Hormone and Peptide Program, Harbor-UCLA Medical Center, Torrance, CA). A separate aliquot underwent ethanol/HCl extraction to remove binding proteins and was tested for IGF-I levels, using rat IGF-I enzyme immunoassay (DSL-2900; Diagnostic Systems Laboratories, Webster, TX). The standard curve of the assay was performed in accordance with the manufacturer's provided samples.
Muscle proteolysis
Hind-limb muscles were collected at the time of euthanasia and snap frozen at Ϫ70 C before being tested for the presence of the 14-kDa actin fragment, an indicator of muscle protein degradation as described (5, 40 -42) . Briefly, the 14-kDa actin fragment was detected in the insoluble fraction of gastrocnemius muscles. Muscles were homogenized in PBS containing proteinase inhibitor cocktail (Roche, Indianapolis, IN) and centrifuged, and the pellet was dissolved in 2ϫ SDS loading buffer. The mixture was boiled for 20 min and centrifuged at top speed for 5 min. Proteins in the supernatant were separated by 15% SDS-PAGE , and the 14-kDa actin fragment was detected by immunoblot analysis using antibodies that detect the carboxy terminus of actin (Sigma Chemical Co., St. Louis, MO). We did not collect muscles from rats treated with BIM-28125 and had only a partial set of muscles from animals treated with BIM-28131. Consequently, we examined only muscles from the nephrectomized (Neph)/saline, Neph/ghrelin, and sham/saline groups to assess for the presence of increased protein breakdown.
Statistics
One-way ANOVA was used to determine differences among the nephrectomy and sham groups, using a Bonferoni post hoc test; P Ͻ 0.05 was considered significant. In the case of the serum cytokines, each individual set of data was considered by ANOVA, and the composite of all of the cytokine levels together was considered after normalizing all levels to the sham/saline group, using a mixed-model analysis for a trend for cytokines values among the different groups. This model takes into account the propensity of some animals to have higher or lower cytokine levels across all of the different cytokines and accounts for within-sample variability.
Results

Production of CKD
Subtotal nephrectomy produced CKD in these rats. There was a significant 5-fold increase in blood urea nitrogen (BUN) [Neph/saline 76.75 Ϯ 11.81 mg/dl, n ϭ 8 (P Ͻ 0.001 vs. sham/saline); Neph/ghrelin 64.36 Ϯ 3.88 mg/dl, n ϭ 11 (P Ͻ 0.01 vs. sham/saline); Neph/BIM-28125 63.13 Ϯ 7.89 mg/dl, n ϭ 10 (P Ͻ 0.01 vs. sham/saline); Neph/BIM-28131 67.13 Ϯ 8.57 mg/dl, n ϭ 8 (P Ͻ 0.01 vs. sham/saline); sham/ saline 13.40 Ϯ 1.03 mg/dl, n ϭ 5] and a 4-fold increase in serum creatinine (Neph/saline 1.18 Ϯ 0.16 mg/dl, n ϭ 8 (P Ͻ 0.001 vs. sham/saline); Neph/ghrelin 1.00 Ϯ 0.043 mg/dl, n ϭ 11 (P Ͻ 0.001 vs. sham/saline); Neph/BIM-28125 1.05 Ϯ 0.089 mg/dl, n ϭ 10 (P Ͻ 0.001 vs. sham/saline); Neph/ BIM-28131 0.96 Ϯ 0.084 mg/dl, n ϭ 8 (P Ͻ 0.01 vs. sham/ saline); sham/saline 0.24 Ϯ 0.024 mg/dl, n ϭ 5] (Fig. 1, A and   B ). There was no significant difference between the Neph/ ghrelin group and the Neph/saline group.
Body weights and food intake
After subtotal nephrectomy, rats receiving ghrelin, BIM-28125, and BIM-28131 exhibited steady improvement in weight, although the weight gain vs. Neph animals receiving saline was significant only for the BIM-28125-treated groups. Sham-operated rats exhibited an improvement in weight relative to all groups [Neph/saline 11.53 Ϯ 2.51 g, n ϭ 8; Neph/ghrelin 21.58 Ϯ 1.75 g, n ϭ 11; Neph/BIM-28125 24.93 Ϯ 2.80 g, n ϭ 10 (P Ͻ 0.01 vs. Neph/saline); Neph/ BIM-28131 19.40 Ϯ 3.31 g, n ϭ 8; sham/saline 47.17 Ϯ 2.01 g, n ϭ 5 (P Ͻ 0.001 vs. all other groups)] (Fig. 2, A and B) .
Treatment with ghrelin and ghrelin-receptor agonist after subtotal nephrectomy significantly improved food intake compared with the Neph/saline group [Neph/saline 139.08 Ϯ 6.25 g, n ϭ 8; Neph/ghrelin 165.74 Ϯ 4.33 g, n ϭ 11 (P Ͻ 0.05 vs. Neph/saline); Neph/BIM-28125 165.34 Ϯ 5.72 g, n ϭ 10 (P Ͻ 0.05 vs. Neph/saline); Neph/BIM-28131 166.64 Ϯ 7.52 g, n ϭ 8 (P Ͻ 0.05 vs. Neph/saline); sham/saline 224.44 Ϯ 8.52 g, n ϭ 5 (P Ͻ 0.001 vs. all other groups)] (Fig. 2C) . The sham-surgery group had a significant increase in food intake relative to the all of the nephrectomy groups. 
DEXA
After subtotal nephrectomy, CKD rats receiving saline had no increase in body mass as measured by DEXA, but CKD rats receiving ghrelin, BIM-28125, or BIM-28131 exhibited a significant increase in body mass [Neph/saline ϩ0.98 Ϯ 1.16%, n ϭ 8; Neph/ghrelin ϩ22.21 Ϯ 2.65%, n ϭ 11 (P Ͻ 0.001 vs. Neph/saline); Neph/BIM-28125 ϩ27.07 Ϯ 2.63%, n ϭ 10 (P Ͻ 0.001 vs. Neph/saline); Neph/BIM-28131 ϩ20.97 Ϯ 3.22%, n ϭ 8 (P Ͻ 0.001 vs. Neph/saline); sham/ saline ϩ48.85 Ϯ 3.09%, n ϭ 5 (P Ͻ 0.001 vs. Neph/saline)] (Fig. 3A) . Sham-operated rats had a significant increase in body mass relative to each of the nephrectomy groups (P Ͻ 0.05).
There was a significant increase in lean body mass for CKD rats receiving ghrelin, BIM-28125, and BIM-28131 and the sham-operated rats. There was no increase in lean body mass of the Neph/saline-treated rats. CKD rats receiving ghrelin, BIM-28125, or BIM-28131 exhibited an increase in lean body mass over that seen in the Neph/saline-treated rats, as did sham-operated rats relative to all groups [Neph/saline ϩ2.79 Ϯ 0.98%, n ϭ 8; Neph/ghrelin ϩ26.30 Ϯ 2.50%, n ϭ 11 (P Ͻ 0.001 vs. Neph/saline); Neph/BIM-28125 ϩ28.96 Ϯ 2.65%, n ϭ 10 (P Ͻ 0.001 vs. Neph/saline); Neph/BIM-28131 ϩ23.62 Ϯ 3.34%, n ϭ 8 (P Ͻ 0.001 vs. Neph/saline); sham/ saline ϩ51.79 Ϯ 2.14%, n ϭ 5 (P Ͻ 0.001 vs. Neph/saline)] (Fig. 3B) .
CKD rats receiving saline or ghrelin has a significant decrease in their fat mass, whereas those receiving BIM-28125 and BIM-28131 and the sham group exhibited no significant change in fat mass. There was no significant difference in the change in fat mass in the CKD groups relative to each other, although there was a significant increase in the sham-operated animals relative to the Neph/saline and Neph/ghrelin groups (Neph/saline Ϫ30.48 Ϯ 4.82%, n ϭ 8; Neph/ghrelin Ϫ30.40 Ϯ 5.57%, n ϭ 11; Neph/BIM 28125 ϩ2.01 Ϯ 9.12%, n ϭ 10; Neph/BIM 28131 Ϫ14.28 Ϯ 7.20%, n ϭ 8; sham/saline ϩ26.83 Ϯ 25.52%, n ϭ 5) (Fig. 3C) .
There was a significant increase in bone mineral content in all groups relative to baseline values; among the CKD groups, however, there was no significant difference among their changes in bone mineral content. Sham-operated rats exhibited an increase in bone mineral content relative to the Neph/saline group [Neph/saline ϩ22.17 Ϯ 3.81%, n ϭ 8; Neph/ghrelin ϩ32.05 Ϯ 3.78%, n ϭ 11; Neph/BIM-28125 ϩ29.11 Ϯ 2.90%, n ϭ 10; Neph/BIM-28131 ϩ26.00 Ϯ 3.56%, n ϭ 8; sham/saline ϩ42.78 Ϯ 2.32, n ϭ 5 (P Ͻ 0.05 vs. Neph/saline)] (Fig. 3D) .
Cytokines
Among the proinflammatory cytokines measured, trends were found in all measured cytokines, but there was no significant difference in any single cytokine within the different treatment groups (IL-1␣: Neph/saline 5.75 Ϯ 1.14 pg/ ml, n ϭ 10; Neph/ghrelin 3.92 Ϯ 2.39 pg/ml, n ϭ 11; Neph/ BIM-28125 3.50 Ϯ 2.49 pg/ml, n ϭ 9; Neph/BIM-28131 3.84 Ϯ 1.62 pg/ml, n ϭ 11; sham/saline 2.00 Ϯ 1.39 pg/ml, n ϭ 5; IL-1␤: Neph/saline 65.81 Ϯ 10.84 pg/ml, n ϭ 19; Neph/ ghrelin 49.52 Ϯ 10.03 pg/ml, n ϭ 22; Neph/BIM-28125 57.37 Ϯ 7.48 pg/ml, n ϭ 9; Neph/BIM-28131 46.58 Ϯ 9.87 pg/ml, n ϭ 11; sham/saline 25.72 Ϯ 7.89 pg/ml, n ϭ 10; IL-6: Neph/saline 241.00 Ϯ 90.87 pg/ml, n ϭ 20; Neph/ghrelin 52.42 Ϯ 18.68 pg/ml, n ϭ 22; Neph/BIM-28125 83.65 Ϯ 21.71 pg/ml, n ϭ 9; Neph/BIM-28131 98.41 Ϯ 36.66 pg/ml, n ϭ 11; sham/saline 58.37 Ϯ 20.05 pg/ml, n ϭ 10; GM-CSF: Neph/ saline 12.85 Ϯ 3.60 pg/ml, n ϭ 19; Neph/ghrelin 5.24 Ϯ 1.93 pg/ml, n ϭ 22; Neph/BIM-28125 7.01 Ϯ 2.05 pg/ml, n ϭ 9; Neph/BIM-28131 8.01 Ϯ 2.83 pg/ml, n ϭ 11; sham/saline 7.82 Ϯ 3.78 pg/ml, n ϭ 10; TNF-␣: Neph/saline 70.84 Ϯ 14.90 pg/ml, n ϭ 19; Neph/ghrelin 34.71 Ϯ 14.00 pg/ml, n ϭ 22; Neph/BIM-28125 47.04 Ϯ 3.36 pg/ml, n ϭ 9; Neph/BIM-28131 45.81 Ϯ 6.23 pg/ml, n ϭ 11; sham/saline 47.83 Ϯ 13.73 pg/ml, n ϭ 10) (Fig. 4, A-E) . However, when we examined the results using a mixed-model ANOVA to detect significant trends among the proinflammatory cytokines for each treatment group, we found a significant decrease in proinflammatory cytokines in ghrelin-treated CKD rats and shamoperated rats relative to the Neph/saline group (P Ͻ 0.05) (Fig. 4F) .
For the antiinflammatory cytokine IL-10, there was a significant increase found in CKD rats receiving BIM-28125 or BIM-28131 relative to the Neph/saline group [Neph/saline 357.27 Ϯ 62.38 pg/ml, n ϭ 19 (P Ͻ 0.01 vs. Sham/saline); Neph/ghrelin 242.41 Ϯ 27.51 pg/ml, n ϭ 22; Neph/BIM-28125 594.83 Ϯ 55.22 pg/ml, n ϭ 9 (P Ͻ 0.05 vs. Neph/saline, P Ͻ 0.001 vs. Neph/ghrelin, P Ͻ 0.001 vs. sham/saline); Neph/BIM-28131 419.26 Ϯ 38.71 pg/ml, n ϭ 11 (P Ͻ 0.01 vs. sham/saline); sham/saline 113.99 Ϯ 20.92 pg/ml, n ϭ 10] (Fig. 4G) .
Gene expression
Appetite-regulating neuropeptides. Neph animals receiving ghrelin exhibited an increase in expression of the orexigenic neuropeptide AgRP relative to the sham group; however, this was not significantly increased over Neph/saline levels [results given as fold increase: Neph/saline 1.53 Ϯ 0.54, n ϭ 16; Neph/ghrelin 1.68 Ϯ 0.62, n ϭ 19 (P Ͻ 0.05 vs. sham/ saline); BIM-28131 1.69 Ϯ 0.52, n ϭ 8; sham/saline 1.00 Ϯ 0.25, n ϭ 10] (Fig. 5B) . There was no significant difference in NPY expression among any of the groups (Neph/saline 1.11 Ϯ 0.35, n ϭ 17; Neph/ghrelin 0.92 Ϯ 0.24, n ϭ 19; Neph/BIM-28131 0.97 Ϯ 0.33, n ϭ 8; sham/saline 1.00 Ϯ 0.31, n ϭ 11) (Fig. 5A) . There was no difference in expression of PC-1 between groups (Neph/saline 0.98 Ϯ 0.23, n ϭ 18; Neph/ghrelin 1.08 Ϯ 0.23, n ϭ 19; Neph/BIM-28131 1.03 Ϯ 0.061, n ϭ 8; sham/saline 1.0 Ϯ 0.24, n ϭ 11) (Fig. 5C ). Regarding PC-2, however, the Neph/saline group had an increased expression of PC-2 relative to the BIM-28131 and the sham/saline groups [Neph/saline 1.46 Ϯ 0.53, n ϭ 18; Neph/ghrelin 1.22 Ϯ 0.26, n ϭ 19; Neph/BIM-28131 0.97 Ϯ 0.33, n ϭ 8 (P Ͻ 0.01 vs. Neph/saline); sham/saline 1.00 Ϯ 0.49, n ϭ 11 (P Ͻ 0.01 vs. Neph/saline)] (Fig. 6D) . There was no difference between any of the groups in expression of POMC in the hypothalamus (Neph/saline 1.06 Ϯ 0.66, n ϭ 15; Neph/ghrelin 0.95 Ϯ 0.68, n ϭ 15; Neph/BIM-28131 0.35 Ϯ 0.095, n ϭ 7; sham/saline 1.00 Ϯ 0.59, n ϭ 7) (Fig. 5E (Fig. 5F ).
Central inflammatory transcripts. There was no difference among the groups for transcript levels of IL-1 ␤ in the hypothalamus (Neph/saline 1.34 Ϯ 0.74, n ϭ 18; Neph/ghrelin 0.98 Ϯ 0.46, n ϭ 19; Neph/BIM-28131 1.54 Ϯ 0.42, n ϭ 8; sham/saline 1.00 Ϯ 0.32, n ϭ 11) (Fig. 6A) , IL-1R in the hypothalamus (Neph/saline 1.01 Ϯ 0.31, n ϭ 17; Neph/ ghrelin 0.78 Ϯ 0.26, n ϭ 19; Neph/BIM-28131 0.77 Ϯ 0.17, n ϭ 8; sham/saline 1.00 Ϯ 0.22, n ϭ 10) (Fig. 6B) , or IL-1␤ in the brainstem (Neph/saline 1.22 Ϯ 0.75, n ϭ 14 n ϭ 17; Neph/ ghrelin 1.27 Ϯ 0.60, n ϭ 12; Neph/BIM-28131 1.34 Ϯ 0.46, n ϭ 8; sham/saline 1.00 Ϯ 0.33, n ϭ 8) (Fig. 6C) . However, there   FIG. 4 . Serum cytokine levels. Serum was collected at the time of euthanasia for Neph animals receiving saline (n ϭ 24) ghrelin (n ϭ 26), or BIM-28131 as well as for sham-treated animals (n ϭ 6). Serum was tested using ELISA for inflammatory cytokine levels as follows: A, IL-1␣; B, IL-1␤; C, IL-6; D, GM-CSF; E, TNF-␣. F, Results for each of the proinflammatory cytokines were then normalized to the sham/ saline average and combined. These data were analyzed using a mixed-model ANOVA, a statistical approach that includes a random effect to account for the clustering of data within each group. G, ELISA analysis of IL-10, an antiinflammatory cytokine. Significance is shown compared with Neph/saline: *, P Ͻ 0.05. (Fig. 6D) .
GH
There was an increase in random GH levels among animals treated with ghrelin relative to the sham group [Neph/ saline 11.7 Ϯ 1.05, n ϭ 10; Neph/ghrelin, 12.9 Ϯ 1.07 n ϭ 11 (P Ͻ 0.05 vs. sham/saline); Neph/BIM-28125 10.78 Ϯ 0.46, n ϭ 9; Neph/BIM-28131 12.18 Ϯ 1.39, n ϭ 11; sham/saline 7.9 Ϯ 1.34, n ϭ 10] (Fig. 7A) , but there was no difference in IGF-I levels among the groups (Neph/saline 244.4 Ϯ 5.02, n ϭ 10; Neph/ghrelin 237.1 Ϯ 6.89, n ϭ 11; Neph/BIM-28125 240.7 Ϯ 8.01, n ϭ 9; Neph/BIM-28131 234.7 Ϯ 8.67, n ϭ 11; sham/saline 217.9 Ϯ 6.10, n ϭ 10) (Fig. 7B) .
Muscle proteolysis
There was a decrease in the level of the 14-kDa actin fragment in muscle of CKD rats treated with ghrelin relative to levels in muscle of the Neph/saline animals. In these analyses, we corrected for differences in loading by calculating the ratio of intact actin to the level of the 14-kDa fragment (Neph/saline 1.299 Ϯ 0.129, n ϭ 22; Neph/ghrelin 0.906 Ϯ 0.06, n ϭ 13; sham/saline 1.016 Ϯ 0.023, n ϭ 13) (Fig.  8) . We did not have a full set of muscles from CKD rats treated with BIM-28131. The level of the 14-kDa actin fragment in available muscles from a subset of BIM-28131 animals was intermediate between the Neph/saline and Neph/ ghrelin animals (1.141 Ϯ 0.107, n ϭ 8). If we included this limited set results in our ANOVA (i.e. analyzed all four groups with any data), the significance between the Neph/ saline and Neph/ghrelin animals was absent.
Discussion
Advanced, stage 4 CKD affects more than 500,000 Americans, and there are approximately 350,000 patients with end-stage renal disease being treated by maintenance hemodialysis (43, 44). Among patients with advanced CKD, 10 -70% suffer from symptoms of cachexia including anorexia and loss of lean body mass, affecting both quality of life and survival (15, 45, 46) . There has been some success in treating patients with end-stage renal disease using anabolic steroids or GH to increase lean body mass, but no treatment has proven successful in improving other symptoms of cachexia (1, 15, (45) (46) (47) (48) .
We have studied the use of both ghrelin and ghrelinreceptor agonists to improve weight gain and lean body mass accrual in a rat model of CKD. These results mirror those seen when these compounds were administered in a rat model of cancer cachexia and raise the potential that ghrelin-receptor agonists may prove useful in treating cachexia in multiple settings. Ghrelin's efficacy in the treatment of the complications of CKD is intriguing given that circulating ghrelin levels have been shown to be elevated when there is renal insufficiency (34). A limitation of our study is that we did not test higher doses of the compounds (having used 150 nmol/ kg⅐d for CKD vs. 500 nmol/kg⅐d for cancer cachexia) or more extended periods of treatment to determine whether there would be more significant benefits. Such studies would be important for designing clinical trials of ghrelin in CKD patients and might suggest how ghrelin could be used prophylactically, administered over extended periods of time and in conjunction with dialysis or other treatments.
A potential mechanism for the improvement in food intake and lean body mass despite the presence of CKD could be via the central melanocortin system in the hypothalamus and brainstem. This system involves two classes of neurons; the first includes anorexigenic neurons that produce POMC, which is cleaved to form ␣-MSH to stimulate melanocortin-4 receptors, producing anorexia and a decrease in muscle mass (27, 49) . The other class of neurons in the melanocortin system are orexigenic, producing AgRP, a natural antagonist of the melanocortin-4 receptor (thereby blocking signals from POMC neurons). Another orexigenic hormone is NPY, which increases feeding behavior by acting on the Y1 receptor. In our previous experiments investigating ghrelin's role in treating cancer cachexia, we showed that tumor-bearing animals treated with 500 nmol/kg⅐d ghrelin had an increase in expression of both AgRP and NPY relative to CKD rats treated with saline (35). In the present study, we treated the animals with 150 nmol/kg⅐d and did not find a significant difference in expression of these orexigenic transcripts in CKD rats treated with ghrelin vs. saline. In addition to dose differences, the lack of a difference in orexigenic transcripts may represent a difference in the severity of the cachexia because animals with cancer have a more severe loss of body weight.
We also did not find any significant difference in the expression of POMC between Neph animals treated with ghrelin and those treated with saline, although there was a generalized decrease in POMC transcripts among all Neph rats relative to sham-operated rats. This decrease in POMC transcript was likely related to the decrease in food intake among cachectic rats because pair-feeding experiments in rats with cancer cachexia revealed a similar decrease in POMC transcript in sham/pair-fed animals relative to sham animals fed ad libitum.
Regarding the lack of changes in gene expression between Neph animals treated with ghrelin and those given saline, it is important to note that ghrelin may exert effects on the melanocortin system via an increase in neuropeptide release without measurable differences in long-term gene expression. Among animals treated with the ghrelin-mimetic BIM-28131, we did find a decrease in the expression of PC-2, an enzyme involved in the cleavage of POMC to ␣-MSH. PC-2 has been shown to be regulated during manipulation of the melanocortin system (50 -52) . A decrease in PC-2 transcript levels suggests there could be a decrease in the processing of POMC and thus possibly a decrease in the secretion of anorexigenic hormones. Nevertheless, changes in gene expression of PC-2 itself may not be reflected in the overall level of translational and posttranslational processing of the peptides involved. In future studies, it will be important to measure the overall peptide content in these appetite-regulating nuclei.
However, it may also be that there is a change in ghrelin's mechanism of action in short-term vs. long-term treatment of cachexia. The model of cancer cachexia involved 5 d of treatment with ghrelin, whereas the model of CKD involved 14 d of treatment. It is possible that there is a shift in ghrelin's effects on melanocortin output over time, with a dampening of ghrelin's stimulation of the orexigenic peptide expression during longer courses of treatment. Interestingly, however, the Neph groups treated with ghrelin and ghrelin receptor agonists did have a significant increase in food intake and lean body mass over Neph/saline animals, results that may be explained by a previous increase in orexigenic expression that decreased over time. Alternatively, it may be that the improvements in food intake and lean mass are not driven significantly by the melanocortin system.
Another means by which ghrelin may produce its effects is via changes in the animal's inflammatory state. There is a strong link between inflammation and cachexia, including both an association of inflammatory markers and cytokines with evidence of cachexia and evidence for a direct stimulation of central neurological centers, including the melanocortin system, by specific cytokines (14, 15, 53) . Circulating cytokines can permeate the relatively weak blood-brain barrier at the level of the hypothalamus, or cytokines expressed centrally could activate the system (54). Indeed, many of the interventions attempted thus far to improve cachexia have targeted the associated inflammation (1).
The potential for ghrelin to decrease inflammatory processes is raised because GHS-1a receptors are expressed on leukocytes; macrophages pretreated with ghrelin exhibited a decreased release of inflammatory cytokines after lipopolysaccharide stimulation (36). We have investigated inflammatory changes associated with cancer cachexia and found a decrease in expression of the IL1-RI in the hypothalamus and brainstem among tumor-bearing rats treated with ghrelin relative to their saline-treated controls. In our CKD model, we noted a similar decrease in IL1-RI expression in the brainstem among ghrelin-treated animals, suggesting that ghrelin reduces the response to inflammation. In the cancer cachexia model, there also was a decrease in central expression of cytokine receptors, but this did not appear to be mediated by peripheral inflammatory signals, because there were no differences in circulating cytokine levels (35).
In CKD rats, we found an overall decrease in circulating proinflammatory cytokines in CKD animals treated with ghrelin, yielding levels that approximate those of sham-treated animals. There also was an increase in circulating levels of the antiinflammatory cytokine IL-10 among CKD rats treated with BIM-28125. Besides the longer period of treatment, it is not clear why there was a decrease in inflammation in CKD rats but not in the model of cancer cachexia. It is also not clear why this increase in IL-10 levels occurred after treatment with BIM-28125 but not with ghrelin itself, although this may be due to increased serum half-life or tighter receptor-binding constants of the ghrelin-receptor antagonists. Given that inflammation is related to cachexia, an antiinflammatory response to ghrelin may represent a major mechanism for the beneficial responses to ghrelin as well as a desirable potential for future applications of ghrelin.
Ghrelin's improvement in lean body mass accrual in the CKD rats was due at least partly to a decrease in muscle catabolism (Fig. 8) . CKD is known to stimulate muscle protein degradation via activation of caspase-3 and the ubiq-uitin-proteasome pathway (55, 56) . In CKD and other catabolic conditions such as cancer and chronic heart failure, there appears to be a link to elevated cytokines causing activation of intracellular proteases including caspase-3 and apoptosis (programmed cell death) (57) (58) (59) (60) . Caspase 3 cleaves actinomyosin in muscle to produce a 14-kDa fragment that is quickly degraded by the ubiquitin-proteasome pathway (5). The 14-kDa actin fragment is found in muscle of animals with increased protein degradation and in patients with catabolic conditions (5, 40 -42, 61) . We observed a decrease in this marker of muscle proteolysis in CKD rats treated with ghrelin compared with CKD rats treated with saline, compatible with previously demonstrated muscle proteolysis (3, 5, 8, 40 -42, 61, 62) . However, it should be pointed out that if the partial set of muscles from Neph/ 28131 animals was included in this ANOVA, the significance between Neph/ghrelin-and Neph/saline-treated animals was lost. Nevertheless, we did find it interesting that given that muscle protein degradation worsens in catabolic conditions and is related to increases in circulating inflammatory factors, the decrease in muscle degradation we found may be induced in part by ghrelin's antiinflammatory effect.
Other potential mechanisms that could account for the influence of ghrelin on the improvement in lean body mass include a potential improvement in kidney function. A recent report concluded that ghrelin improved kidney function (63). We did not observe significant differences in BUN or creatinine in our experiments, suggesting that the improvement in lean body mass retention was related to factors other than a change in renal function.
In evaluating ghrelin's effect on the GH-IGF-I axis, we found an increase in random levels of GH in the Neph/ ghrelin rats relative to sham-treated rats (but not relative to the Neph/saline animals). However, there were no significant differences in IGF-I levels between any of the treatment groups, suggesting (as we also observed in the model of cancer cachexia) that ghrelin's effects are not mediated by IGF-I in these models.
The goal of cachexia research is to improve the lives of humans suffering from cachexia. Small-molecule agonists of the ghrelin receptor GHS-1a had equal efficacy to ghrelin, using compounds that have a longer half-life and oral bioavailability with better potential for clinical use. Ghrelin itself has a short half-life and is not bioavailable, limiting its potential clinical application. The benefit of the present results suggest that these agonists could prevent or ameliorate the development of cachexia in CKD
Conclusion
In conclusion, we have used a rat model of surgically induced renal failure and found that ghrelin treatment improves food intake, total body mass, and lean body mass. Administration of human ghrelin or two synthetic ghrelinreceptor agonists exerted similar benefits. The improvement in lean body mass accrual was in part mediated by a decrease in muscle protein degradation. Ghrelin treatment also caused an overall decrease in circulating cytokines, which may be one mechanism of action of its effects and further highlights potential benefits for therapeutic use.
